The Stamp Out Lyme Disease Act requires the United States Postal Service to issue a semipostal stamp and designates the excess proceeds to finance research on Lyme and related tick‑borne illnesses at the National Institute of Allergy and Infectious Diseases (NIAID). The stamp must be made available for at least six years and sales revenues are transferred to NIAID at least twice annually.
This bill creates a new, voluntary revenue stream targeted to tick‑borne disease research while insulating that revenue from being treated as a substitute for congressional appropriations. For organizations tracking federal research funding, public health program managers, and postal operations teams, the statute sets clear delivery and disbursement mechanics that will govern implementation and oversight.
At a Glance
What It Does
The bill directs USPS to issue a Lyme Disease Research semipostal stamp under the authority of 39 U.S.C. §416; the stamp will carry a surcharge above postage and the surplus proceeds are earmarked for NIAID. Proceeds must be transferred to NIAID at least twice per year and are not to be counted against NIAID’s appropriations.
Who It Affects
USPS will administer production, pricing, and sales; NIAID will receive and administer the funds for Lyme and related tick‑borne disease research; donors and postal customers will pay the voluntary surcharge at purchase. Public health researchers, diagnostic developers, and patient‑advocacy groups are likely downstream beneficiaries.
Why It Matters
Semipostals are a rare statutory tool to collect voluntary public support for research without creating a new federal grant program. The structure alters funding flows to NIAID by adding a dedicated, visible revenue stream and raises practical questions about scale, oversight, and integration with existing research priorities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill instructs the Postal Service to produce and sell a semipostal stamp whose sale price includes a surcharge above the postal value; that surcharge (the amount ‘‘becoming available’’ under 39 U.S.C. §416) is the revenue intended for Lyme disease and related tick‑borne illness research. Because the statute ties issuance to the existing semipostal framework, design, pricing, and sales logistics will follow USPS rules and implementing regulations for semipostals.
Funds collected through the stamp are to be transferred to the National Institute of Allergy and Infectious Diseases. The bill requires at least biannual transfers and explicitly prevents those proceeds from being counted when Congress or agencies set NIAID’s appropriations, which preserves the money as supplementary, not a replacement, for regular budgeted funds.The stamp must be available to the public for a minimum of six years and USPS must begin sale no later than 12 months after the law takes effect.
That duration gives the program a multiyear runway to build awareness and revenues but leaves key operational choices — retail distribution, online sales, marketing, pricing above face value, and inventory logistics — to USPS discretion under §416 and its regulations.The statute is narrowly focused: it creates no new grant mechanisms, reporting requirements, or detailed spending rules for NIAID beyond the destination of proceeds. NIAID will therefore need to integrate these supplemental dollars into its existing research portfolio for Lyme and related tick‑borne diseases and determine internal monitoring, prioritization, and public reporting practices consistent with its policies and federal grant rules.
The Five Things You Need to Know
The legislation relies on 39 U.S.C. §416 to authorize a semipostal stamp whose surcharge proceeds are the funding source for research.
Proceeds from sales are to be transferred to NIAID at least twice per year rather than held by USPS.
The statute states that proceeds must not be counted in decisions about annual appropriations to NIAID (references 39 U.S.C. §416(d)(4)).
USPS must make the stamp available to the public for at least six years, and sales must begin no later than 12 months after enactment.
The bill confines use of the funds to Lyme disease and related tick‑borne illness research managed by NIAID; it creates no new advisory board, reporting mandate, or earmarked grant program outside NIAID’s existing authorities.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
A single-line provision that names the law the Stamp Out Lyme Disease Act. This is purely stylistic but establishes the label by which downstream regulations, appropriations language, and publicity will refer to the program.
Findings and purpose
Congress sets out the public‑health rationale and frames the policy objective: to provide an easy, voluntary channel for public contributions toward Lyme and tick‑borne disease research. The findings cite incidence, diagnostic challenges, chronic symptoms, and estimated economic costs to justify targeted fundraising. Practically, this subsection signals Congressional intent to supplement federal research funding rather than replace it.
Issuance governed by semipostal statute
This subsection folds the stamp program into the existing semipostal statute (39 U.S.C. §416), meaning USPS will follow its established internal procedures and any regulations governing semipostal design, pricing, sale channels, and duration. For implementers, that delegation leaves operational decisions (retail placement, commemorative art, marketing) to USPS within the statutory framework, rather than prescribing them in law.
Disposition and non‑offset of proceeds
All surcharge proceeds, as computed under the referenced statutory method, must be transferred to NIAID for Lyme and related tick‑borne research; transfers occur at least twice yearly. The subsection also invokes the non‑offset rule in 39 U.S.C. §416(d)(4), preventing Congress or executive agencies from treating these voluntary receipts as a reduction in NIAID’s appropriated budget — a key protection ensuring the funds act as supplemental revenue.
Duration and definition
The stamp must remain available for minimum six years and distribution must begin within a year of enactment, creating a fixed multiyear window to raise funds. The bill also clarifies that ‘semipostal stamp’ carries the meaning provided in §416(a)(1), anchoring the program to the existing statutory definition rather than introducing new terminology.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- National Institute of Allergy and Infectious Diseases (NIAID) — receives a dedicated, supplemental revenue stream specifically earmarked for Lyme and related tick‑borne disease research, expanding its funding options without requiring a new appropriations line item.
- Lyme disease researchers and clinical investigators — gain potential additional grant or program funding from NIAID that can support diagnostics, therapeutics, and epidemiological studies not covered by current grants.
- Patient advocacy groups and affected communities — benefit from a high‑visibility fundraising vehicle that can increase public awareness and channel voluntary donations to research priorities.
- Public donors and stamp collectors — receive a concrete, recognized method to support research via routine retail purchases, with collectors adding a cause‑oriented issue to their collections.
Who Bears the Cost
- Postal customers who choose to buy the stamp — pay the surcharge embedded in the semipostal price; the program depends on voluntary purchases rather than mandatory fees.
- United States Postal Service — must allocate operational resources for design, production, distribution, marketing, and accounting for the semipostal stamp under §416, which historically entails administrative burdens and upfront costs recovered from sales but may require internal prioritization.
- NIAID and NIH administrative units — must absorb the responsibility for receiving, accounting for, and allocating the funds within existing grant management structures, potentially requiring internal policy decisions about prioritization and reporting without new statutory instructions.
- Congressional appropriations committees and federal budget officials — while not direct payers, they face the policy complexity of integrating supplemental voluntary funding into long‑term research planning and oversight without setting precedent for substituting appropriations with semipostal revenues.
Key Issues
The Core Tension
The central dilemma is between mobilizing visible, voluntary public support for a targeted public‑health problem and the risk that such voluntary streams will be treated as a convenient supplement that substitutes for sustained, predictable appropriations; the bill increases funding options but leaves unresolved whether the funds will be large enough, transparent enough, or administratively supported enough to change research outcomes.
The bill creates a narrow, voluntary funding mechanism but leaves substantial implementation details unspecified. It does not require USPS to set a particular surcharge level, direct distribution channels, marketing strategy, or reporting on sales and impacts; those choices will determine how much revenue the program actually raises.
Likewise, the statute identifies NIAID as the recipient but omits any new requirements for transparency, earmarking rules within NIAID, or metrics tying expenditures to outcomes. That raises questions about how the Institute will integrate and prioritize these dollars alongside existing grants and whether donors can trace impact.
Another tension involves scale and expectations. Semipostal stamps historically raise modest sums relative to federal research budgets; the bill risks creating symbolic but limited funding that could be oversold as a solution to structural gaps in Lyme disease research funding.
The law’s non‑offset clause reduces the risk of substitution, but it does not prevent informal budgetary tradeoffs in future appropriations decisions. Finally, operational burdens fall on USPS and NIH without explicit new resources for administration, and the six‑year minimum term sets a finite window that may not align with long‑term research funding needs or program evaluation timelines.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.